Graft-versus-cancereffect and innovative approaches in the treatment of refractory solid tumors

Şahin, Uğur; Demirer, Taner

doi:10.3906/sag-1911-112

Cited by 3 publications

(1 citation statement)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, ACI procedures based on allogeneic donor cells were effectively amalgamated with low-dose nonmyeloablative chemotherapy to boost graft-versus-tumor (but not graft-versus-host) reactivity [ 30 , 31 ]. In this scenario, graft-versus-tumor effect was mediated by donor-derived T cells, which were also shown to engage recipient immune cells into long-term anti-tumor reactivity [ 32 ]. According to our experience, ACI protocols utilized in elderly people could benefit from the administration of allogeneic cells from a closely related person.…”

Section: Boosting Anti-tumor Immunitymentioning

confidence: 99%

Inflammation Control and Immunotherapeutic Strategies in Comprehensive Cancer Treatment

et al. 2023

View full text Add to dashboard Cite

Tumor growth and expansion are determined by the immunological tumor microenvironment (TME). Typically, early tumorigenic stages are characterized by the immune system not responding or weakly responding to the tumor. However, subsequent tumorigenic stages witness the tumor promoting its growth and metastasis by stimulating tumor-protective (pro-tumor) inflammation to suppress anti-tumor immune responses. Here, we propose the pivotal role of inflammation control in a successful anti-cancer immunotherapy strategy, implying that available and novel immunotherapeutic modalities such as inflammation modulation, antibody (Ab)-based immunostimulation, drug-mediated immunomodulation, cancer vaccination as well as adoptive cell immunotherapy and donor leucocyte transfusion could be applied in cancer patients in a synergistic manner to amplify each other’s clinical effects and achieve robust anti-tumor immune reactivity. In addition, the anti-tumor effects of immunotherapy could be enhanced by thermal and/or oxygen therapy. Herein, combined immune-based therapy could prove to be beneficial for patients with advanced cancers, as aiming to provide long-term tumor cell/mass dormancy by restraining compensatory proliferation of surviving cancer cells observed after traditional anti-cancer interventions such as surgery, radiotherapy, and metronomic (low-dose) chemotherapy. We propose the Inflammatory Prognostic Score based on the blood levels of C-reactive protein and lactate dehydrogenase as well as the neutrophil-to-lymphocyte ratio to effectively monitor the effectiveness of comprehensive anti-cancer treatment.

show abstract

Section: Boosting Anti-tumor Immunitymentioning

confidence: 99%